Can This Obesity-Drug Maker Beat Arena and VIVUS in Europe?

Obesity-drug specialists Arena Pharmaceuticals (NASDAQ: ARNA  ) and VIVUS (NASDAQ: VVUS  ) have already launched their products in the United States, but both have struggled to get the green light in the European Union. While the two fight for market share in the U.S., Orexigen Therapeutics (NASDAQ: OREX  ) , the third major player in this space, announced last week that it has submitted an application with the European Medicines Agency for the approval of its obesity medication Contrave. Orexigen has yet to get its drug approved by the FDA, but could it beat both Arena and VIVUS to the European market? Analysts David Williamson and Max Macaluso discuss this story in the following video.

Incredible growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!


Read/Post Comments (3) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 07, 2013, at 4:50 AM, WallSTcz wrote:

    Can This Obesity-Drug Maker Beat Arena and VIVUS in Europe?

    NO

    WallST in EU 7 oct. 2013

  • Report this Comment On October 07, 2013, at 5:49 AM, RSRdriver wrote:

    Vivus's EU problem appeared to be off label use ("the potential for use where it is not intended"). This should be an easy fix for them.

    Arena's Belviq has a serious problem with marginal efficacy and likely,still unanswered safety issues. Being a 2C receptor drug is probably their biggest reason for EU rejection though, ( research 2C drug rejection in Europe). IMO, there is no way Belviq gets EU approval and Swiss approval is likely not to happen for the same reasons. When that happens, several countries who use Swiss drug guidelines will also reject Belviq.

    If Orexigen's obesity drug can prove itself safe and on the right side of a cost /benefit ratio, there is no reason why it should not be approved by the EU. Whether it will beat Vivus (IMO, the only other viable player in this question) remains to be seen.

  • Report this Comment On October 07, 2013, at 10:52 AM, i5par wrote:

    VVUS EU problem is the formula is too close to banned Fen-Fen. Europe will have nothing to do with Phen-based compounds. Add that Qysmia has no other morbidity to claim such as Diabetes.

    As for Contrave, Europe will do nothing until it has a US approval. Bet your house on that. Analysts praising Contrave should note that the FDA has put the bar so far out of reach for study results that approval is no better than 50-50.

    Plus neither company has the cash or pipeline to do much more than hope that analysts pumps can save the stocks before the curtain drops.

Add your comment.

DocumentId: 2670279, ~/Articles/ArticleHandler.aspx, 4/20/2014 2:13:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement